Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
US11028076B2 · kind B2 · utility
1Cited by
23References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2020 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Jan 17, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.